Suppression of myoclonus in SCA2by Piracetam

Movement Disorders

Volumn 21, Issue 1, 2006, Pages 116-118

  De Rosa, Anna ^a   Striano, Pasquale ^a   Barbieri, Fabrizio ^a   de Faco, Arturo ^a   Rinaldi, Carlo ^a   Tucci, Tecla ^a   Striano, Salvatore ^a   Filla, Alessandro ^a   De Michele, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Myoclunus; Nootropic drugs; Piracetam; SCA2

Indexed keywords

CLONAZEPAM; ETIRACETAM; PIRACETAM; VALPROIC ACID; NERVE PROTEIN; SCA2 PROTEIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; CEREBELLUM DEGENERATION; COGNITIVE DEFECT; DISEASE SEVERITY; DROWSINESS; DRUG DOSE REGIMEN; DYSMETRIA; DYSTONIA; ELECTROENCEPHALOGRAM; ELECTROMYOGRAM; EYE MOVEMENT DISORDER; GAIT DISORDER; HUMAN; HYPOTROPHY; MALE; MULTICHANNEL RECORDER; MUSCLE TONE; MUSCLE WEAKNESS; MYOCLONUS; PRIORITY JOURNAL; SPINOCEREBELLAR DEGENERATION; TREATMENT FAILURE; TREMOR; ATAXIA; DOSE RESPONSE; DRUG EFFECT; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; NEUROLOGIC EXAMINATION; RECURRENT DISEASE; TREATMENT OUTCOME; TRINUCLEOTIDE REPEAT; WITHDRAWAL SYNDROME;

ADULT; ATAXIA; DOSE-RESPONSE RELATIONSHIP, DRUG; GAIT ATAXIA; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MYOCLONUS; NERVE TISSUE PROTEINS; NEUROLOGIC EXAMINATION; PIRACETAM; RECURRENCE; SPINOCEREBELLAR ATAXIAS; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; TRINUCLEOTIDE REPEATS;

EID: 33244476269     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20683     Document Type: Article

References (14)

1. Pulst SM, Nechiporuk T, Nechiporuk A, et al. Moderate expansion of a normally biallelic trinucleotiide repeat in spinocerebellar ataxia type 2. Nat Genet 1996;4:269-276.
2. Coppola G, Filla A. Disorders of the cerebellum. In: Joynt RJ, Griggs RC, editors. Baker and Joynt's clinical neurology on CD-ROM. Philadelphia, PA: Lippincott, Williams and Wilkins; 2004. Chapter 37.
3. Ikeda A, Shibasaki H, Tashiro K, Mizuno Y, Kimura J, the Myoclonus/Piracetam Study group. Clinical trial of piracetam in patients with myoclonus: nationwide multiinsfitution study in Japan. Mov Disord 1996;11:691-700.
4. Brown P, Steiger MJ, Thompson PD, et al. Effectiveness of piracetam in cortical myoclonus. Mov Disord 1993;8:63-68.
5. Trouillas P, Takayanagi T, Hallett M, et al. International cooperative ataxia rating scale for pharmacological assessment of the cerebellar syndrome: the Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997;145:205-211.
6. Yabe I, Sasaki H, Chen DH, et al. Spinocerebellar ataxia type 14 caused by a mutation in protein kinase C γ. Arch Neurol 2003;60: 1749-1751.
7. Schelhaas HJ, Ippel PF, Hageman G, Sinke RJ, van der Laan EN, Beemer FA. Clinical and genetic analysis of a four-generation family with a distinct autosomal dominant cerebellar ataxia. J Neurol 2001;248:113-120.
8. Shibasaki H, Hallett M. Electrophysiological studies of myoclonus. Muscle Nerve 2005;31:157-174.
9. Caviness JN, Brown P. Myoclonus: current concepts and recent advances. Lancet Neurol 2004;3:598-607.
10. Wilkins D, Hallett M, Erba G. Primary generalised epileptic myoclonus: a frequent manifestation of minipolymyoclonus of central origin. J Neurol Neurosurg Psychiatry 1985;48:506-516.
11. Muller W, Koch S, Scheuer K, Rostock A, Bartsch R. Effects of piracetam on membrane on membrane fluidity in the aged mouse, rat and human brain. Biochem Pharmacol 1997;53:135-140.
12. Genton P, Van Vleymen B. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profile. Epileptic Disord 2000;2:99-105.
13. Genton P, Gelisse P. Antimyoclonic effect of levetiracetam. Epileptic Disord 2000;2:209-212.
14. Vural M, Ozekmekci S, Apaydin H, Altinel A. High-dose piracetam is effective on cerebellar ataxia in a patient with cerebellar cortical atrophy. Mov Disord 2003;18:457-459.